AI Startup Waiv Spins Out of Owkin with $33M to Advance Precision Cancer Decision-Making
Waiv, which originated as the diagnostics division of AI-driven biotech company Owkin, has spun out as an independent entity with substantial new capital to propel its AI-based cancer diagnostic tools. This spinout will enable the company to focus more sharply on advancing precision medicine and clinical applications in oncology.
In a notable development within the AI and biotech sectors, Waiv has emerged as a standalone company following its spinout from Owkin, a well-known AI-powered biotechnology firm. The new entity has raised $33 million in funding, underscoring investor confidence in its mission to enhance cancer treatment decisions through artificial intelligence.
Waiv's technological foundation centers on AI-enabled testing platforms that leverage advanced algorithms to analyze digital pathology images and clinical data. These technologies have already demonstrated utility in both clinical cancer care settings and drug development research.
The spinout strategy aims to create organizational focus, agility, and resource allocation dedicated specifically to Waiv's innovative precision oncology solutions. Co-founder and CEO Meriem Sefta highlighted this independence as a critical enabler for pursuing growth opportunities and partnerships tailored to their niche.
Precision medicine in oncology relies on detailed, accurate diagnostic data to inform therapeutic choices that maximize efficacy and minimize harm. AI-driven tools like those developed by Waiv promise to accelerate this process by identifying subtle patterns and biomarkers often missed by conventional methods.
By integrating machine learning with pathology and clinical research, Waiv's platforms support oncologists in making data-driven decisions that ultimately improve patient outcomes. This advancement comes at a time when cancer remains a leading cause of morbidity and mortality globally, heightening the demand for precision diagnostic technologies.
The spinout from Owkin not only reflects the maturation of AI applications in healthcare but also signals a broader trend wherein specialized startups are carving out focused niches to drive innovation in biomedicine.
For more comprehensive insights into Waiv's trajectory and technology, please refer to MedCity News at https://medcitynews.com/2026/03/ai-startup-waiv-owkin-precision-medicine-oncology-digital-pathology/
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.